Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
2 citations
,
February 2023 in “Actas Dermo-Sifiliográficas” Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
2 citations
,
November 1990 in “International Journal of Dermatology” Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.
16 citations
,
April 2000 in “Contact dermatitis” A man developed severe skin reactions after using a treatment for hair loss.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
February 2024 in “Curēus” Topical 5-Fluorouracil can rarely cause nerve damage, especially in people with a certain genetic deficiency.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.
March 2025 in “OncoTargets and Therapy” A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.
44 citations
,
November 2009 in “Archives of Dermatology” CYLD mutations cause a variety of skin tumors with symptoms starting around age 16, and treatments are currently limited.
2 citations
,
January 2022 in “JAAD Case Reports” The rash resolved after stopping ponatinib.
February 2024 in “Journal of dermatology research reviews & reports” A 50-year-old woman with breast cancer developed an autoimmune skin disorder, highlighting the need for thorough checks and team-based treatment.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
January 2026 in “Preprints.org” Posaconazole effectively treated a resistant fungal infection in a Spitz dog.
61 citations
,
July 2022 in “Journal of Nanobiotechnology” Fucoidan-derived carbon dots can effectively treat root canal infections by killing bacteria and are safer than traditional disinfectants.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
June 2019 in “International journal of dermatology and venereology” A man developed skin issues from cancer medication, which improved with specific treatments.
37 citations
,
January 1986 in “Carcinogenesis” ODC expression in mouse skin and tumors is varied and can be inhibited by retinoic acid or cycloheximide.
January 2024 in “Scripta Medica” Nanoparticle delivery can reduce side effects of the cancer drug doxorubicin.
2 citations
,
November 2024 in “In Silico Pharmacology”
51 citations
,
March 2006 in “Bioorganic & Medicinal Chemistry” Newly made nicotinamide compounds could potentially treat cancer.
May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
2 citations
,
September 2018 in “JAAD case reports” A rare type of skin cancer with mucosal involvement was partially treated but eventually relapsed.
July 2024 in “Journal of Investigative Dermatology” Taxane chemotherapy can cause permanent hair loss by damaging hair follicles and altering their DNA.
September 2005 in “電子情報通信学会ソサイエティ大会講演論文集” Cancer prevention has advanced significantly, with some strategies proving successful.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.
December 2025 in “Biomolecules” Compound 7p shows strong potential as an anticancer agent.
4 citations
,
January 2011 in “International Journal of Clinical Medicine” Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
Deuruxolitinib is approved to treat severe alopecia areata in adults.